Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of an investigational eye treatment called DE-109 — a low dose (44 micrograms), a medium dose (440 micrograms), and a higher dose (880 micrograms). The trial had two stages: a "double-masked" phase (where neither participants nor researchers knew which dose was being given) and an open-label phase (where the dose was known). In the double-masked phase, 208 people started in the low-dose group, 208 in the medium-dose group, and 176 in the higher-dose group. The trial was measuring levels of "vitreous haze" — a cloudiness or haziness inside the eye that can affect vision — using a standardised scoring scale, where a score of 0 means no cloudiness at all. The reported data shows that the main result the trial was designed to measure was how many participants in each group had a vitreous haze score of zero (meaning no detectable cloudiness) at the five-month mark. According to the results reported on ClinicalTrials.gov, 28 participants in the low-dose group, 44 in the medium-dose group, and 27 in the higher-dose group reached that score of zero at month five. Additional measurements were also reported — for example, at month five, the number of participants who either reached a score of zero or showed a meaningful improvement of at least two steps on the scale was 43, 56, and 33 for the low, medium, and higher dose groups respectively. The reported data also shows that at month five, 84, 104, and 70 participants across the three groups had a score of zero or only the faintest trace of cloudiness. Similar counts were recorded at the six-month mark across all three measures, with the numbers varying across groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with active uveitis (inflammation inside the eye) that has been confirmed by a doctor
- You are 18 years of age or older
- You are willing and able to sign a consent form agreeing to take part in the study
- Your vision meets a specific level when tested with an eye chart, even with glasses or contacts (confirm with trial site)
Who may not be able to join:
- Your uveitis is caused by an infection
- You have, or are suspected to have, lymphoma (a type of cancer) affecting the brain, spine, or eyes
- Your main diagnosis is uveitis affecting only the front part of the eye (anterior uveitis)
- You have glaucoma that is not well controlled
- You are currently using eye drop medications
- You have a medical device implanted in or around your eye (confirm with trial site)
- You have another serious eye condition beyond uveitis
- You have cloudiness or other problems with the lens or inner parts of the eye that block a clear view inside
- You have had eye surgery or certain eye treatments recently (confirm with trial site)
- You have had a specific laser eye procedure called a capsulotomy
- You currently have an infection in or around your eye
- You are unable to have your pupils dilated for eye examinations
- You have a history of herpes (cold sore virus) infections
- You have or have had toxoplasmosis, a parasitic infection, or scarring from it
- You have or have had a cancerous growth in or around your eye
- You have a known allergy or sensitivity to the medication being studied
- You have taken part in another uveitis clinical trial within the last 30 days
- You are currently receiving certain advanced drug treatments such as monoclonal antibodies or biologic therapies
- You have any ongoing systemic (whole-body) illness or infection (confirm with trial site)
- You are taking medications that suppress your immune system, or your immune system is weakened for any reason
- You have a history of cancer that is currently in remission
- You are pregnant, breastfeeding, or not using adequate birth control (applies to women who could become pregnant)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.